OncoCyte Corp (NYSEAMERICAN:OCX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “

Separately, ValuEngine downgraded shares of OncoCyte Corp from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th.

Shares of OncoCyte Corp (NYSEAMERICAN OCX) opened at $4.40 on Friday. OncoCyte Corp has a 52 week low of $3.60 and a 52 week high of $7.95.

TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/11/18/oncocyte-corp-ocx-lowered-to-sell-at-zacks-investment-research.html.

A hedge fund recently raised its stake in OncoCyte Corp stock. Broadwood Capital Inc. grew its stake in OncoCyte Corp (NYSEAMERICAN:OCX) by 17.7% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,596,680 shares of the biotechnology company’s stock after acquiring an additional 540,000 shares during the period. OncoCyte Corp comprises 4.5% of Broadwood Capital Inc.’s investment portfolio, making the stock its 5th biggest holding. Broadwood Capital Inc. owned approximately 11.48% of OncoCyte Corp worth $27,155,000 as of its most recent filing with the SEC.

About OncoCyte Corp

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.

Get a free copy of the Zacks research report on OncoCyte Corp (OCX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with MarketBeat.com's FREE daily email newsletter.